Recently, the PROLONG Trial, investigating 17-OHP’s role in preventing recurrent preterm birth, called into question the effectiveness of this treatment regimen. However, most of the study patients in the manufacturer’s initiated study were outside of the United States and were significantly different than the original MFMU study participants. In this session, we will review both of these studies and put the results into proper perspective.